A screen for combination therapies in BRAF/NRAS wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combination
Marco Ranzani, Kristel Kemper, Magali Michaut, Oscar Krijgsman, Nanne Aben, Vivek Iyer, Kim Wong, Theodoros I. Roumeliotis, Martin Del Castillo Velasco-Herrera, Jérémie Nsengimana, Gemma Turner, Nicola Thompson, Aida Shahrabi, Marcela Sjoberg, Mamunur Rashid, , David J. Adams
bioRxiv · Sep 28, 2017 · PreprintCancer Biology